Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

84.75USD
4:01pm EDT
Change (% chg)

$0.51 (+0.61%)
Prev Close
$84.24
Open
$84.20
Day's High
$85.00
Day's Low
$84.05
Volume
863,326
Avg. Vol
1,396,772
52-wk High
$86.13
52-wk Low
$64.25

Latest Key Developments (Source: Significant Developments)

Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent
8:10am EDT 

Intelgenx Technologies Corp : Intelgenx Technologies- Eli Lilly granted Intelgenx' Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent . Intelgenx Technologies Corp - any exclusivity associated with tadalafil compound patent expiring is not affected by this agreement - SEC filing . Intelgenx Technologies- exclusive license allows co to commercialize tadalafil ed versafilm product in U.S. prior to expiration of '166 dosing patent Source: (http://bit.ly/2nvYskj) Further company coverage: [IGX.V] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Adocia 2016 revenue down at 22.4 million euros
Tuesday, 14 Feb 2017 12:00pm EST 

Adocia SA : 2016 revenue of 22.4 million euros ($23.7 million), compared to 36.9 million euros in 2015 . Solid cash position of 58 million euros at December 31, 2016 . FY operating income 30.4 million euros versus 44.7 million euros year ago .Following announcement in January of Eli Lilly's decision to terminate the agreement, the remaining non-amortized part of up-front payment, (for a total of 18.8 million euros), to be fully recognized in 2017.  Full Article

European Commission approves once-daily olumiant tablets for treatment of rheumatoid arthritis
Monday, 13 Feb 2017 04:21pm EST 

Incyte Corp : European Commission approves once-daily olumiant tablets for treatment of adults with moderate-to-severe active rheumatoid arthritis . Incyte -as a result of approval of olumiant by European Commission, Incyte becomes eligible to receive a milestone payment of $65 million from Lilly .Incyte Corp - Phase 3 trial for patients with psoriatic arthritis is expected to be initiated in 2017.  Full Article

Lilly reports dividend increase
Monday, 12 Dec 2016 06:00pm EST 

Eli Lilly And Co : Lilly announces dividend increase . Increases quarterly dividend by 2 percent . Eli Lilly and Co - dividend for Q1 of 2017 will be $0.52 per share on outstanding common stock . Eli Lilly and Co - 2 percent increase in its quarterly dividend .Eli Lilly and Co - dividend for Q1 of 2017 will be $0.52 per share on outstanding common stock..  Full Article

FDA approves Synjardy XR tablets for adults with type 2 diabetes
Monday, 12 Dec 2016 03:28pm EST 

Eli Lilly And Co : Synjardy XR can cause serious side effects, including Lactic Acidosis .U.S. FDA approves Synjardy XR (Empagliflozin/Metformin hydrochloride extended-release) tablets for adults with type 2 diabetes.  Full Article

Elanco Animal Health enters agreement to acquire Boehringer Ingelheim Vetmedica's U.S. feline, canine and rabies vaccines portfolio
Wednesday, 5 Oct 2016 06:45am EDT 

Eli Lilly And Co : Elanco Animal Health enters agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. feline, canine and rabies vaccines portfolio . Deal for $885 million . Lilly expects acquisition to be accretive to GAAP earnings in 2019 and to non-GAAP earnings in 2018 . Acquisition is anticipated to close by early 2017, subject to approval by Federal Trade Commission .Also included in agreement are several pipeline assets.  Full Article

Macrocure says appointed Douglas Onsi as CFO of combined entity
Monday, 29 Aug 2016 08:51am EDT 

Macrocure Ltd : Leap Therapeutics and Macrocure announce definitive merger agreement . Macrocure Ltd says under terms of agreement, Macrocure will become a wholly owned subsidiary of Leap . Under terms of agreement, Macrocure shareholders will exchange their macrocure shares for newly issued shares of Leap common stock . Combined company is expected to have a minimum of $30 million of cash at closing to finance future operations . Executive team of leap therapeutics will remain in their positions in combined entity . Christopher K. Mirabelli will serve as chief executive officer and chairman of board of directors of combined Co . Equity holders expected to own about 31.8%, and Leap equity holders are expected collectively to own about 68.2%, of combined Co . Says at closing, two macrocure designated individuals, including nissim mashiach, will join Leap's board of directors . Douglas E. Onsi will serve as chief financial officer of combined Co . Existing Leap investors have committed to invest an additional $10 million at closing of transaction . Entities affiliated with healthcare ventures,Eli Lilly, which own all Leap's outstanding voting shares, entered agreements in support of deal . Under terms of agreement, leap will become a public company .Says appointed Douglas E. Onsi, chief financial officer of combined entity.  Full Article

AstraZeneca, Lilly receive FDA fast track designation for AZD3293
Monday, 22 Aug 2016 06:03am EDT 

AstraZeneca Plc :AstraZeneca and Lilly receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer'S disease.  Full Article

Lilly and Astrazeneca receive FDA fast track designation for AZD3293
Monday, 22 Aug 2016 06:00am EDT 

Eli Lilly And Co: Lilly and Astrazeneca receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer's disease .Also announced planned initiation of a second phase 3 trial for azd3293.  Full Article

Lilly-Health Canada approves new indication for Jardiance tablets
Thursday, 11 Aug 2016 07:00am EDT 

Eli Lilly And Co :Health Canada approves new indication for Jardiance (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease.  Full Article

More From Around the Web

BRIEF-Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent

* Intelgenx Technologies- Eli Lilly granted Intelgenx' Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent